Sekkei Bio has secured Series A funding co-led by Tenshi Pharmaceuticals and Ashish Kacholia to enhance its biologics discovery platform targeting diabetes and metabolic diseases.

Information on the Target

Sekkei Bio has successfully closed its Series A funding round, which was co-led by Tenshi Pharmaceuticals and respected investor Ashish Kacholia, with additional participation from deep-tech investor Manish Gandhi. The company is focused on developing a platform-driven biologics discovery engine that targets diabetes and metabolic diseases. Notably, it is working on a groundbreaking once-a-day oral insulin pill, which has the potential to significantly enhance accessibility and adherence for diabetic patients worldwide.

This funding comes at a crucial moment as India continues to solidify its deep-tech ecosystem. With the establishment of a national DeepTech Advisory Board and rising investor interest in intellectual property-led innovation, frontier science, and research and development-intensive ventures are becoming increasingly prominent in the country.

Industry Overview in India

The Indian biotechnology sector is rapidly evolving, driven by advancements in science and technology, making it one of the most promising industries for innovation. The government is providing substantial support through initiatives aimed at foster